How an AI Tumor Board Builds Multidisciplinary Consensus for NSCLC

Why NSCLC staging drives everything

Non-small cell lung cancer (NSCLC) accounts for roughly 80–85% of lung cancers, and the TNM stage at diagnosis is the single strongest predictor of prognosis and the right treatment path. An early-stage tumor may be cured with surgery, while locally advanced disease usually needs multimodal therapy combining chemotherapy, radiation, and sometimes immunotherapy.

The multidisciplinary tumor board advantage

Real-world tumor boards bring medical, surgical, and radiation oncologists together to agree on a plan. The AI Tumor Board simulates that structure: separate specialist agents analyze the same case in parallel — evaluating resectability, nodal involvement, biomarker-driven options, and radiation fields — then a synthesis layer reconciles disagreements into a single consensus recommendation.

From parallel analysis to one recommendation

• Medical oncology weighs systemic therapy, biomarker targets, and trial options.
• Surgical oncology assesses resectability and the role of lymph node dissection.
• Radiation oncology defines curative or palliative fields and sequencing.

The result is a documented, evidence-linked plan you can review and adapt — not a black box.